Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
Hand-out
Press Releases
Myris Therapeutics, Inc.  
February 20, 2025

Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer

Myris Therapeutics emerges from stealth to announce new name and strategic focusProprietary polymer chemistry enables ultra-high drug to antibody ratios of 50 - 100 and new chemical space for precision

avatar profile Olean Times Herald

Olean Times Herald


Local & Social